Arumugam Palanichamy
Arumugam Palanichamy
Spark Therapeutics
Verified email at
Cited by
Cited by
Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis
P Roll, A Palanichamy, C Kneitz, T Dorner, HP Tony
Arthritis & Rheumatism: Official Journal of the American College of …, 2006
Novel human transitional B cell populations revealed by B cell depletion therapy
A Palanichamy, J Barnard, BO Zheng, T Owen, T Quach, C Wei, ...
The Journal of Immunology 182 (10), 5982-5993, 2009
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients
A Palanichamy, S Jahn, D Nickles, M Derstine, A Abounasr, SL Hauser, ...
The Journal of Immunology 193 (2), 580-586, 2014
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis
A Palanichamy, L Apeltsin, TC Kuo, M Sirota, S Wang, SJ Pitts, ...
Science translational medicine 6 (248), 248ra106-248ra106, 2014
B cells in the pathogenesis and treatment of rheumatoid arthritis
B Marston, A Palanichamy, JH Anolik
Current opinion in rheumatology 22 (3), 307, 2010
Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response
DG Adlowitz, J Barnard, JN Biear, C Cistrone, T Owen, W Wang, ...
PloS one 10 (6), e0128269, 2015
Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus
A Palanichamy, JW Bauer, S Yalavarthi, N Meednu, J Barnard, T Owen, ...
The Journal of Immunology 192 (3), 906-918, 2014
Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets
H von Büdingen, A Palanichamy, K Lehmann-Horn, BA Michel, SS Zamvil
European neurology 73 (3-4), 238-246, 2015
Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody
AS Rouzière, C Kneitz, A Palanichamy, T Dörner, HP Tony
Arthritis research & therapy 7 (4), 1-11, 2005
Small molecule mediated inhibition of RORγ‐dependent gene expression and autoimmune disease pathology in vivo
D Banerjee, L Zhao, L Wu, A Palanichamy, A Ergun, L Peng, C Quigley, ...
Immunology 147 (4), 399-413, 2016
Modulation of molecular imprints in the antigen‐experienced B cell repertoire by rituximab
A Palanichamy, P Roll, R Theiss, T Dörner, HP Tony
Arthritis & Rheumatism: Official Journal of the American College of …, 2008
Intrathecal B-cell activation in LGI1 antibody encephalitis
K Lehmann-Horn, SR Irani, S Wang, A Palanichamy, S Jahn, ...
Neurology-Neuroimmunology Neuroinflammation 7 (2), 2020
Failure of B cell tolerance in CVID
CT Richardson, MA Slack, G Dhillon, CZ Marcus, J Barnard, ...
Frontiers in Immunology 10, 2881, 2019
Collagen turnover biomarkers associate with active psoriatic arthritis and decrease with guselkumab treatment in a phase 3 clinical trial (DISCOVER-2)
G Schett, MJ Loza, A Palanichamy, O FitzGerald, C Ritchlin, ...
Rheumatology and Therapy 9 (4), 1017-1030, 2022
Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains
A Palanichamy, K Muhammad, P Roll, S Kleinert, T Dörner, HP Tony
The Journal of Rheumatology 39 (6), 1130-1138, 2012
B cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: Transient recirculation of plasmablasts and increased levels of germinal center …
P Roll, A Palanichamy, AS Rouziere, T Dörner, C Kneitz, HP Tony
ARTHRITIS AND RHEUMATISM 52 (9), S289-S289, 2005
Characterization of human late transitional B cells: Implications for systemic lupus
A Palanichamy, J Barnard, T Owen, B Zheng, T Conley, T Quach, C Wei, ...
ARTHRITIS AND RHEUMATISM 58 (9), S446-S446, 2008
Interferon activation in human SLE bone marrow inhibits B cell lymphopoiesis
J Barnard
American College of Rheumatology National Meeting 2008, 2008
Effect of Ocrelizumab on B-and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial
SA Laurent, NB Strauli, EL Eggers, H Wu, B Michel, S Demuth, ...
Neurology-Neuroimmunology Neuroinflammation 10 (4), 2023
Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells.
E Ezealah, J Hossler, J Biear, CA Cistrone, T Owen, N Meednu, ...
ARTHRITIS AND RHEUMATISM 64 (10), S516-S516, 2012
The system can't perform the operation now. Try again later.
Articles 1–20